Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

REVIUM Rx

reviumrx.com
Filed: May 27, 2026CIK: 0001839140Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

REVIUM Rx announced the appointment of Igor Bluvstein as Chief Financial Officer effective May 27, 2026, following the resignation of Arie Gordashnikov. This leadership transition may signal a shift in financial strategy as the company continues operations.

Key Takeaways

Arie Gordashnikov resigned as CFO effective immediately with no disagreements cited regarding company operations or policies

Igor Bluvstein appointed as new CFO, bringing prior CFO experience from Argent BioPha (2024-2025)

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 27, 2026
Item5.02
CategoryExecutive Change
CIK0001839140
Accession #333-284934
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
executive departureleadership transitionexecutive hire

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings